Mitochondrial dysfunction and energy depletion in the failing heart are innovative therapeutic targets in heart failure management. Elamipretide is a novel tetrapeptide that increases mitochondrial energy; however, its safety, tolerability, and therapeutic effect on cardiac structure and function have not been studied in heart failure with reduced ejection fraction.
N
early half of all patients with heart failure have a reduced ejection fraction (EF), and despite current therapies, these patients have a diminished quality of life and poor long-term prognosis with an absolute mortality rate of approximately 50% within 5 years of diagnosis. 1, 2 In heart failure with reduced EF (HFrEF), there is activation of neurohumoral responses that attempt to compensate for impaired cardiac performance, but these compensatory mechanisms also increase myocardial energy expenditure. 3, 4 Normal cardiac function is reliant on having an adequate supply of energy in the form of adenosine triphosphate (ATP). The amount of ATP in the myocyte is relatively small compared with demand, which can be 10 000× greater; therefore, myocardial cells must continually resynthesize ATP to maintain normal pump function and cellular viability. 3 However, in the failing heart, energy generation is impaired leading to a progressive loss of ATP, which results in diminished contractile reserve and myocardial pump dysfunction. 5 Elamipretide (MTP-131, Bendavia) is a novel tetrapeptide that targets mitochondrial dysfunction in energy-depleted myocytes and has the potential to augment cardiac function in patients with HFrEF. In vitro and in vivo studies have demonstrated that elamipretide can ameliorate or prevent many measures of mitochondrial dysfunction, including a reduction in ATP levels. [6] [7] [8] [9] In preclinical studies, elamipretide significantly improved left ventricular (LV) systolic function, prevented pathological LV remodeling after myocardial infarction, increased myocardial ATP synthesis, and restored mitochondria-related gene expression. 10, 11 Based on these results, we hypothesize that elamipretide may present a novel approach to treating HFrEF by reversing the myocardial energy deficit and improving cardiac function. To study this, we conducted the first trial of elamipretide in patients with HFrEF to examine the safety, efficacy, and tolerability of this treatment when added to guidelinedirected heart failure therapy.
METHODS

Study Design and Patient Selection
This study was a prospective, randomized, double-blind, placebo-controlled, single ascending-dose trial that included patients with HFrEF and stable New York Heart Association classes II to III heart failure. Patients were randomized (2:1) to a single 4-hour intravenous infusion of elamipretide or an equivalent volume placebo infusion. Enrollment occurred in 3 successive cohorts of increasing elamipretide dose (0.005, 0.05, and 0.25 mg·kg
). Patients with New York Heart Association class II or III heart failure who had an LV EF ≤35% on a baseline screening 2-dimensional echocardiogram were recruited for the study. Eligible patients were required to be between 45 and 80 years of age, have either nonischemic or ischemic cardiomyopathy of at least 6 months duration, and have been treated with guideline-based pharmacological heart failure therapy at stable doses for a minimum of 1 month before enrollment. Heart failure therapy included treatment with β-blocker and angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, with or without a mineralocorticoid antagonist. Patients were not eligible if they had a heart failure hospitalization, acute myocardial infarction, or cerebrovascular event in the prior 3 months. Patients with atrial fibrillation or cardiac resynchronization therapy were also excluded. Additional inclusion and exclusion criteria are provided in Table I in the Data Supplement.
The study was conducted at a single site: Bulgarian Cardiac Institute, Medical University of Pleven, Bulgaria. All patients provided written informed consent to participate. Screening evaluations were performed within 28 days of enrollment. Enrolled patients were randomized and admitted to the clinical study unit for a baseline evaluation on day 1. On day 2, predose assessments were conducted within 2 hours before study drug infusion. Each patient then received a single 4-hour intravenous infusion of elamipretide or placebo. Both the study drug and placebo, manufactured by Patheon, were provided to the site as a lyophilized powder in identical sterile glass vials and reconstituted with 250 mL of normal saline before administration. Study participants and site investigators were blinded to treatment allocation. Patients were discharged from the clinical study unit after a minimum of 24 hours after the end of study drug administration. Final study evaluations were performed on day 7.
WHAT IS NEW?
• Normal cardiac function is reliant on having an adequate supply of energy from the mitochondria. However, in heart failure, energy generation is impaired, resulting in diminished contractility and adverse cardiac remodeling.
• Mitochondrial dysfunction and energy repletion provide an innovative therapeutic target in heart failure management.
• Elamipretide-a novel peptide that targets energy-depleted mitochondria-may ameliorate mitochondrial dysfunction and increase energy generation within cardiac myocytes.
WHAT ARE THE CLINICAL IMPLICATIONS?
• This trial randomized patients with heart failure with reduced ejection fraction on guideline-based heart failure treatment to either a single infusion of elamipretide or placebo.
• The results demonstrated that a single infusion of elamipretide was safe and well tolerated at 3 different ascending dose levels.
• Additional studies are currently being conducted to determine the long-term safety of elamipretide and the impact on cardiac remodeling.
• If successful, restoration of myocardial energetics may be a promising new approach to the treatment of heart failure.
Study End Points
The primary end point of this study was to evaluate the safety and tolerability of a single 4-hour intravenous infusion of elamipretide in 3 ascending-dose cohorts of patients with HFrEF, as assessed by the occurrence of serious and nonserious adverse events (AEs). Secondary end points included (1) the pharmacokinetic analysis of elamipretide, (2) the effect of elamipretide on cardiac structure and function, and (3) the influence of elamipretide on cardiac and renal biomarkers. All participants and investigators were blinded to study treatment. Safety was assessed by physical examination, blood and urine laboratory testing, electrocardiography, serial 2-dimensional echocardiography, and clinical monitoring for AEs. AEs were adjudicated by a blinded clinical events committee. All AEs were characterized as mild, moderate, or severe according to predefined protocol definitions. The trial was monitored by an independent Data Safety Monitoring Board. Safety data were reviewed by the Data Safety Monitoring Board at the completion of each cohort before initiating enrollment in the subsequent ascending-dose cohort. The Duke University Institutional Review Board approved the study protocol, and Ethics Committee approval was obtained at the study site.
Cardiac biomarkers, including NT-proBNP (N-terminal pro-B-type natriuretic peptide) and high-sensitivity C-reactive protein, were collected on days 2 (predose and 6 hours postinfusion start) and 7. Kidney function was monitored by serial serum creatinine and estimated glomerular filtration rate calculated by the Modification of Diet in Renal Disease Study equation. The exploratory renal biomarkers of urinary 8-isoprostane and 8-hydroxy-2-deoxyguanosine were obtained on day 2 (predose and 6 hours postinfusion start) and analyzed with an enzyme-linked immunosorbent assay.
The pharmacokinetic analysis determined plasma elamipretide concentrations in blood samples collected at predose (immediately before starting the infusion) and 1, 2, 4, 5, 6, 7, 8, 12, 18 , and 24 hours postinfusion start. All pharmacokinetic analyses were independently performed by IDDI Company (Ottignies-Louvain-la-Neuve, Belgium).
Echocardiographic Core Laboratory Analysis
Echocardiographic assessments were performed at predose (before elamipretide infusion), mid-infusion, end-infusion, and 6, 8, 12, and 24 hours postinfusion. All 2-dimensional transthoracic, noncontrast echocardiograms were analyzed by an independent core laboratory at Duke Clinical Research Institute (Durham, NC) according to current American Society of Echocardiography guidelines. 12, 13 Interpreting cardiologists were blinded to treatment allocation. Cardiac structure and function was evaluated by serial assessment of LV end-diastolic volume (LVEDV), LV end-systolic volume (LVESV), EF, left atrial volume, right ventricular (RV) fractional area change, RV systolic pressure (RVSP), valve regurgitation, and LV global longitudinal strain. Left heart volumes and EF were quantified by the biplane Simpson method using Digisonics Digiview software (version 3.8.4; Houston, TX). Spectral Doppler tracings of tricuspid regurgitation were used to determine peak tricuspid regurgitation velocity, and RVSP was estimated using the modified Bernoulli equation.
Valve regurgitation severity was based on an integration of quantitative methods and expert visual interpretation, and then graded on a scale ranging from none to severe. LV longitudinal strain was obtained in the apical 4-and 2-chamber views and averaged to determine a global longitudinal value using TOMTEC software (version 4.6.2; Unterschleissheim, Germany).
All sonographers and interpreting cardiologists adhered to established best practice standards for echocardiography core laboratories, which included reproducibility testing for LVEDV, LVESV, and EF. 13 Inter-reader reproducibility for these echocardiographic parameters demonstrated high reproducibility across all readers (intraclass correlation coefficient: 0.95 for LVEDV, 0.98 for LVESV, and 0.99 for LV EF).
Statistical Analysis
Differences in baseline characteristics among the 3 elamipretide cohorts and pooled placebo patients were assessed using χ 2 tests for categorical variables and Kruskal-Wallis tests for continuous variables. Discrete data are presented as a proportion of observations, and continuous data are expressed as mean±SD or median with interquartile range, as appropriate. The sample size for the primary end point of safety and tolerability of elamipretide was chosen based on data from phase I clinical safety trials of elamipretide. Based on this prior safety data, as well as logistical and feasibility considerations, it was estimated that 36 patients randomized (2:1) into 3 successive ascending-dose cohorts of elamipretide would be needed to evaluate safety in this initial HFrEF population. For secondary end points, paired t tests were used at each time point to evaluate change from baseline within each treatment cohort and 2 group t tests were used to compare whether the change from baseline in each elamipretide cohort was significantly different from the pooled placebo cohort within a 1-way ANOVA framework. Given the exploratory nature of secondary end points, there was no prespecified adjustment for multiple comparisons. Multivariate regression analysis compared the change from baseline between elamipretide cohorts and placebo with adjustment for age, sex, diabetes mellitus, and coronary artery disease. Overall differences in pharmacokinetic parameters of systemic exposure were evaluated by ANOVA across all dosing cohorts. To estimate the power model and assess dose proportionality, a simple linear regression model was fit to the responses log-transformed area under the curve (AUC) and C max with a term for logtransformed dose. For all analyses, statistical significance was defined at an alpha level of 0.05. Statistical analyses were performed using SAS, version 9.4 (SAS Institute, Cary, NC).
RESULTS
Of the 64 patients screened, 36 were enrolled and randomized (2:1) into 3 successive ascending-dose cohorts ( Figure 1 ) from July 2014 through April 2015. The mean age of patients was 62±10 years, 78% were men, mean baseline EF was 29%, and 77% had ischemic cardiomyopathy. The treatment groups were generally well balanced with respect to baseline characteristics, except for resting heart rate and body mass index (Table 1 ).
Greater than 85% of patients were receiving treatment with a β-blocker and angiotensin-converting enzyme inhibitor or angiotensin receptor blocker.
Primary End Point: Safety and Tolerability
Safety data were available for all enrolled patients at study conclusion. AEs were classified as serious or nonserious according to predefined protocol definitions. Elamipretide was well tolerated as a single 4-hour infusion in the low-, intermediate-, and high-dose cohorts (0.005, 0.05, and 0.25 mg·kg −1 ·h −1 , respectively). There were no serious AEs in any of the elamipretide cohorts or among patients receiving placebo. There were 4 nonserious AEs in 3 patients: 1 patient in cohort 1 (low-dose elamipretide) and 2 patients in cohort 2 (intermediate-dose elamipretide). In cohort 1, 1 patient with a history of chronic kidney disease experienced worsening of preexisting renal dysfunction that did not affect study participation (creatinine was 1.6 mg/dL at baseline and on day 3, increased to 2.7 mg/dL on day 7; repeat creatinine at an unscheduled visit 2 months later was 2.6 mg/dL). Dyspnea and tachycardia led to study discontinuation in 1 patient in cohort 2 45 minutes after infusion start. A third patient, also in cohort 2, had a hemoglobin decrease that was considered mild and did not impact participation (hemoglobin decreased from 13.1 g/dL on day 1 to 11.4 g/dL on day 3 to 10.7 g/dL on day 7; repeat hemoglobin 8 days later was 11.4 g/dL). There were no AEs among patients in cohort 3 (high-dose elamipretide) or patients receiving placebo.
Blood pressure and heart rate remained stable in all cohorts (Figure 2 ). There were no clinically significant changes on physical examination during the study period. Mean changes in ECG intervals were small and transient and were not considered clinically significant on independent adjudication.
Secondary End Points
Pharmacokinetic Analyses Plasma elamipretide concentrations increased over time during the infusion period. Peak plasma concentrations of elamipretide occurred at end infusion (4 hours postinfusion start) in all 3 cohorts and were undetectable by 24 hours postinfusion start (Figure 3) . The highest plasma concentrations of elamipretide were seen in cohort 3 patients at end-infusion.
Pharmacokinetic analysis for elamipretide showed a dose-proportional exposure from 0.005 to 0.25 mg·kg . The power model parameter estimates were AUC, 1.00 (95% confidence interval, 0.88-1.12) and C max , 1.00 (95% confidence interval, 0.89-1.12).
Echocardiographic Analyses
The quantitative analysis of cohort 1 was technically limited by suboptimal image quality. To address this limitation in subsequent cohorts, a highly experienced, registered diagnostic cardiac sonographer from Duke Clinical Research Institute provided on-site training to optimize image acquisition before enrollment of patients in cohorts 2 and 3. All cardiac imagers at the study site underwent intensive group and individual training on the echocardiographic protocol, including optimization of 2-dimensional, spectral, and color Doppler images.
Quantitative echocardiographic analyses of LV volumes and EF were obtained at baseline in 75% of patients in cohort 1 and 100% of patients in cohorts 2 and 3. Quantitative LV volumes and EF at all serial time points were measurable in 55% of echocardiograms (46 of 84) in cohort 1, 69% of cohort 2 (58 of 84 echoes), and 81% in cohort 3 (68 of 84 echoes). Comparisons of the mean change from baseline at each time point revealed that the most pronounced effects on cardiac size and function occurred at end-infusion (4 hours postinfusion start). By 24 hours after infusion initiation, the structural and functional changes appreciated on serial echocardiographic imaging had returned to baseline.
In cohort 1, baseline echocardiographic characteristics were not statistically different between patients treated with low-dose elamipretide compared with those receiving placebo, although there was a trend toward a slightly higher EF among elamipretide patients (35.4% versus 26.7%; P=0.08; Table 2 ). Among patients receiving low-dose elamipretide, there was no All data are presented as n (%) unless otherwise noted. ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood pressure; bpm, beats per minute; CABG, coronary artery bypass grafting; CAD, coronary artery disease; IQR, interquartile range; MI, myocardial infarction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; and PCI, percutaneous coronary intervention. *There were no significant differences in baseline clinical characteristics between treatment groups, except for heart rate and BMI.
†Median (IQR). ‡Mean±SD.
Figure 2. Blood pressure and heart rate trends among placebo and elamipretide cohorts.
The temporal trend in blood pressure (A) and heart rate (B) among placebo patients and the low-, intermediate-, and high-dose elamipretide cohorts. There were no significant differences in blood pressure or heart rate within the elamipretide cohorts or when compared with placebo. Box plots represent median with interquartile range. BPM indicates beats per minute.
difference in the absolute change in LV volumes, EF, left atrial size, or RV function at any time point when compared with pooled placebo patients. In cohort 2, there were no significant differences in baseline echocardiographic characteristics between patients receiving the intermediate-dose of elampretide and pooled placebo patients (Table 2) . Among cohort 2 patients, there was a significant decrease in RVSP at end-infusion as compared with placebo patients: −9.9 versus +9.1 mm Hg, P=0.009 (Table 3) .
There were no significant differences in baseline echocardiographic characteristics between cohort 3 patients receiving high-dose elamipretide and pooled placebo patients ( Table 2 ). The most pronounced changes in echocardiographic parameters, particularly LV volumes, occurred at end-infusion (Figure 4) . Compared with placebo, cohort 3 patients had a significant reduction in LVEDV and LVESV but no significant change in EF (Table 3) . RVSP was not significantly different among patients receiving high-dose elamipretide at end-infusion compared with placebo patients. The severity of mitral and tricuspid regurgitation decreased from baseline to end-infusion among patients receiving high-dose elamipretide, whereas there was no improvement in any type of valve regurgitation among patients treated with placebo.
Multivariable adjustment was performed to assess change in indexed LV volumes from baseline to end-dose in patients treated with high-dose elamipretide versus placebo. The adjusted reduction in LVEDV index and LVESV index remained significantly greater among patients treated with high-dose elamipretide compared with those receiving placebo: −9.1 mL (95% confidence interval, −16.7 to −1.5), P=0.023; and −7.4 mL (95% confidence interval, −13.2 to −1.7), P=0.016, respectively.
Biomarker Analyses
Cardiac biomarkers, NT-proBNP, and high-sensitivity C-reactive protein did not significantly differ at any time point among elamipretide or placebo cohorts (Figure 5) . No temporal change in kidney function was seen in any of the cohorts. There was no significant change in renal biomarkers.
DISCUSSION
The mitochondrial dysfunction and energy depletion found in the failing heart are innovative therapeutic targets in heart failure management. This study is the first to evaluate elamipretide-a novel mitochondriatargeting peptide-in patients with heart failure and demonstrates that elamipretide is safe and well tolerated. A single infusion of high-dose elamipretide resulted in significant reductions in LV volumes, which were temporally correlated with peak plasma concentrations. Furthermore, these favorable effects were seen among patients already receiving optimal guideline-based heart failure treatment.
Myocardial Dysfunction and Heart Failure
The concept of energy depletion in the failing heart was first proposed in 1939, and subsequent investigations have confirmed the critical role of energy metabolism in heart failure. 5, [14] [15] [16] Cells with high energy demand, such as cardiac myocytes, have a high mitochondrial content for the rapid and efficient production of ATP. In the failing heart, mitochondria are dysfunctional, and energy demands rapidly exceed ATP supply. This energy supply-demand mismatch results in increased mitochondrial reactive oxygen species and oxidative stress, which are important upstream mediators of myocyte necrosis, pathologic cardiac remodeling, and LV dysfunction. 17 Therefore, targeting the cellular mechanisms of heart failure, particularly the mitochondrial ATP deficit and oxidative stress, may improve or even restore myocardial energetics and potentially facilitate recovery of cardiac function.
Elamipretide is a water-soluble tetrapeptide with structural motifs of natural and synthetic amino acids, which are metabolized by peptidases in the plasma and renally excreted. The cellular uptake of elamipretide is concentration-dependent, energy-independent, and not saturable. Elamipretide readily penetrates cell membranes and localizes to the inner mitochondrial membrane where it associates with cardiolipin. Cardiolipin is critical in maintaining the functional positioning of the electron transport chain complexes and supercomplexes within the inner mitochondrial membrane that allows for efficient electron transfer down the redox chain with minimal generation of reactive oxygen species. Elamipretide prevents the peroxidation of cardiolipin; therefore, maintains membrane fluidity, supercomplex formation, and enhances electron transport chain function in disease. Ultimately, elamipretide has been shown to improve electron flow through the electron transport chain, thereby increasing ATP synthesis and reducing mitochondrial reactive oxygen species. [18] [19] [20] [21] Ex vivo and in vivo animal studies have shown that elamipretide significantly improves myocardial mitochondrial ATP content, reduces myocardial infarct size, and improves cardiac function. 6, 10, 22 In a canine model of HFrEF, elamipretide improved EF and stroke volume without a significant change in heart rate or blood pressure. 11 Additionally, systolic function continued to improve throughout the 3 months of treatment.
Heart Failure and Elamipretide
In this study, all 3 doses of elamipretide were found to be safe and well tolerated as a single 4-hour infusion in patients with HFrEF. There were no serious AEs, and of the few nonserious AEs, none occurred in the highest-dose cohort. Furthermore, even as the dose of elamipretide increased with successive cohorts, heart rate and blood pressure did not significantly change compared with baseline values. Importantly, elamipretide did not negatively impact cardiac hemodynamics in patients with HFrEF on existing heart failure regimens. A similar favor- ) was the same as that used in cohort 2 (intermediate dose). Although myocardial infarct size was not reduced, elamipretide was found to be safe and well tolerated in patients with reduced EF after myocardial infarction with no significant effects on blood pressure or heart rate.
In addition to demonstrating safety and tolerability, elamipretide was also effective in inducing changes in cardiac structure and function. The highest dose of elamipretide resulted in significant decreases in LVEDV and LVESV at end infusion. Reductions in RVSP and decreases in both mitral and tricuspid regurgitation also occurred at end infusion among the intermediate-dose and high-dose elamipretide cohorts, respectively. Pharmacokinetic analyses showed a dose-proportional exposure from 0.005 to 0.25 mg·kg −1 ·h −1 infusion rate with respect to C max and AUC. The increasingly pronounced changes in cardiac structure and function with ascending doses strongly support a dose-response relationship. Furthermore, maximal changes in LV volumes correlated with peak plasma concentrations and abated when plasma concentrations became undetectable. This temporal association suggests that elamipretide can have an effect after only a single administration. A similar response and reduction in LVESV was seen in dogs after a 2-hour infusion of elamipretide and persisted after 3 months of subcutaneous elamipretide treatment. 11 Whether successive exposure can result in a sustained reduction in LV volumes in patients with HFrEF is currently being assessed in a study of daily subcutaneous administration of elamipretide (NCT02788747). In heart failure, functional capacity is limited by diminished cardiac output but also by skeletal muscle weakness and atrophy. Given the high energy demands of skeletal muscle, mitochondrial dysfunction is postulated to be a contributing factor to exercise intolerance in patients with heart failure. 24 Current heart failure treatments modulate neurohormonal and sympathetic activation and improve clinical outcomes, but diminished functional capacity may persist. 1, 25, 26 Furthermore, medication intolerance because of hemodynamic side effects, such as bradycardia and hypotension, can preclude titration to the recommended maximally effective doses and limit the clinical benefit. Thus, there is a need for pharmacotherapies without these limitations. Elamipretide acts by primarily influencing mitochondrial energetics and has the potential to improve both cardiac and skeletal muscle function in patients with HFrEF, thereby increasing exercise tolerance and functional capacity through restoration of the mitochondrial energy supply. Indeed, the promising results of elamipretide have been seen in the treatment of mitochondrial myopathy, which have shown marked improvement in 6-minute walk distance compared with patients receiving placebo (MMPOWER trial [A Study Investigating the Safety, Tolerability, and Efficacy of MTP-131 for the Treatment of Mitochondrial Myopathy], NCT02367014, Mitochondrial Medicine 2016, oral abstract presentation). These findings suggest that elamipretide may have salutary effects on skeletal muscle and provide additional therapeutic benefit that is additive to its impact on cardiac muscle energetics.
Elamipretide has been shown to enhance ATP synthesis in organs with high mitochondrial density, including heart, kidney, and skeletal muscle. In this study, there was a clinically meaningful decrease in LVEDV and LVESV (18 and 14 mL, respectively) in the highdose elamipretide cohort. Although this trial was too small and brief to be definitive, the marked improvement in LV volumes supports the hypothesis that the failing heart is an engine of fuel 5 and that modulation or restoration of myocardial energetics may be a promising new approach to the treatment of heart failure. Further study is needed to evaluate the reverse remodeling potential of elamipretide and assess the impact on clinical outcomes among patients with HFrEF.
Study Limitations
This early phase study was limited by the small number of patients enrolled at a single clinical site. Despite randomization, there was still mild heterogeneity in the baseline characteristics within the cohorts. Although quantitative echocardiographic analysis could not be performed in all patients at every time point secondary to suboptimal image quality, particularly in cohort 1, significant changes in cardiac structure were detected in the highest-dose cohort and correlated with peak plasma concentrations, which supports a temporal association and dose-effect relationship. Diastolic function was not assessed in this study; however, there is a currently enrolling trial that is evaluating diastolic parameters in patients with heart failure with preserved EF randomized to either elamipretide or placebo (NCT02814097). A single intravenous dose of elamipretide seems safe, but cardiac monitoring with telemetry or Holter monitoring and cardiac troponin was not performed. Finally, the infrequent timing of the assessment of biomarkers made it difficult to draw conclusions about the impact of elamipretide on natriuretic peptide levels or novel renal biomarkers.
Conclusions
In conclusion, elamipretide is a novel heart failure therapeutic that was safe and well tolerated in patients with HFrEF on guideline-based heart failure treatment. Concordant changes in LVEDV and LVESV, which correlated with peak plasma concentrations, suggest that highdose elamipretide can have an effect after a single infusion. These findings provide substantial support to the hypothesis that mitochondrial dysfunction and energy depletion is a valid and feasible therapeutic target in HFrEF. Future trials are needed to evaluate the impact of daily elamipretide on cardiac structure and function and downstream clinical outcomes. 
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